Thromboembolism after COVID-19 vaccine in patients with preexisting thrombocytopenia.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
03 08 2021
03 08 2021
Historique:
received:
23
06
2021
accepted:
26
07
2021
revised:
26
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
While vaccination is the single most effective intervention to drastically reduce severe disease and death following SARS-CoV-2 infection, as shown in UK and Israel, some serious concerns have been raised for an unusual adverse drug reaction (ADR), including vaccine-induced immune thrombotic thrombocytopenia (VITT) with concurrent low platelets as well as capillary leak syndrome. In fact, the overall safety of the vaccine is highlighted by the low frequency of ADR considering that in UK, by the early June, 40 million first doses and 29 million second doses have been injected; nonetheless, 390 thrombotic events, including 71 fatal events have been reported. Interestingly, the cases reported low platelet counts with the presence of anti-platelet factor-4 (PF4) antibodies, indicating an abnormal clotting reaction. Here, out of three referred cases, we report a post-vaccine clinical case of fatal thrombosis with postmortem examination and whole exome sequencing (WES) analysis, whose pathogenesis appeared associated to a preexisting condition of thrombocytopenia due to myelodysplasia.
Identifiants
pubmed: 34344867
doi: 10.1038/s41419-021-04058-z
pii: 10.1038/s41419-021-04058-z
pmc: PMC8328816
doi:
Substances chimiques
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
762Informations de copyright
© 2021. The Author(s).
Références
N Engl J Med. 2015 Jul 16;373(3):252-61
pubmed: 26176382
J Thromb Haemost. 2021 Jul;19(7):1813-1818
pubmed: 33909350
N Engl J Med. 2021 May 20;384(20):1964-1965
pubmed: 33852795
Lancet. 2021 May 1;397(10285):e11
pubmed: 33864750
Biochem Biophys Res Commun. 2021 Jan 29;538:145-150
pubmed: 33388129
Nat Commun. 2019 Mar 21;10(1):1322
pubmed: 30899022
Cell. 2021 Jun 24;184(13):3452-3466.e18
pubmed: 34139176
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Blood Adv. 2017 Jun 29;1(16):1224-1237
pubmed: 29296762
Cell Cycle. 2012 Oct 1;11(19):3638-48
pubmed: 22935697
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
BMJ. 2021 Apr 14;373:n958
pubmed: 33853865
Cell. 2021 Apr 1;184(7):1821-1835.e16
pubmed: 33667349
Cell Death Differ. 2021 Feb;28(2):626-639
pubmed: 33479399
Biol Direct. 2020 Dec 29;15(1):30
pubmed: 33371901
J Intern Med. 2015 Mar;277(3):294-305
pubmed: 25495259
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
ACS Pharmacol Transl Sci. 2021 Mar 16;4(3):1079-1095
pubmed: 34136757
J Hematol Oncol. 2020 Sep 4;13(1):120
pubmed: 32887634
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487
Cell Death Dis. 2020 Sep 24;11(9):799
pubmed: 32973152
Cell Death Dis. 2021 Mar 24;12(4):310
pubmed: 33762578